Hetero Wins Approval for Generic Sofosbuvir in India

Hetero, based in Hyderabad, India, has received approval for generic Sofosbuvir Tablets, 400 mg (Gilead’s SOVALDI), from the Drug Controller General of India. Hetero has a non-exclusive license agreement with Gilead Sciences, Ireland to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
 
Hetero will launch Sofosbuvir under its brand Sofovir in India this month with other countries to follow. Hetero has also partnered with other licensee holders to distribute generic Sofosbuvir in India.
 
“Hepatitis C is a growing public health concern, particularly in developing countries such as India and Hetero is committed to bringing affordable sofosbovir to India” said Vamsi Krishna, director of Hetero.